San Mateo Podiatry Group

Make a PaymentCall Today! 650-342-2420 Menu
  • Home
  • About Us
  • New Visitors
  • Services
  • Contact
News / Osteochondral Lesions of the Talus – Allograft no better than micro fracture?

Osteochondral Lesions of the Talus – Allograft no better than micro fracture?

on June 1, 2018

A new multicenter study has ruled out a newer allograft technology in the fight against cartilage injuries.

The study, “Comparison of Juvenile Allogenous Articular Cartilage and Bone Marrow Aspirate Concentrate Versus Microfracture With and Without Bone Marrow Aspirate Concentrate in Arthroscopic Treatment of Talar Osteochondral Lesions,” is published in the April 2018 edition of Foot & Ankle International.

Mark Drakos, M.D., orthopedic surgeon at New York’s Hospital for Special Surgery and co-author, said to OTW, “Cartilage injuries continue to be challenging issues to treat for orthopedic surgeons. The current treatment of microfracture (MF) has several shortcomings including mixed long-term outcomes. We were looking to improve upon the current standard of care by using some of the newer allograft technologies.”

In their study, the authors treated 30 patients with microfracture and treated another 20 patients with received DeNovo NT for juvenile allogenic chondrocyte implantation (ACI) with autologous bone marrow aspirate (BMAC) between 2006 and 2014.

The researchers also gave 17 of the microfracture patients supplemental bone marrow aspirate treatment.

According to the authors, “Both the microfracture and juvenile allogenic chondrocyte implantation with autologous bone marrow aspirate patents showed significant pre- to postoperative improvements in all Foot and Ankle Outcome Score subscales.”

“Visual Analog Scale scores also showed improvement in both groups, but only reached a level of statistical significance in the microfracture group. There were no significant differences in patient reported outcomes between groups….”

Dr. Drakos told OTW, “The most important results were that there was no difference in either clinical outcome or radiographic appearance between using the juvenile particulate cartilage allograft and the conventional microfracture technique.”

The authors wrote, “ACI-BMAC and MF resulted in improved functional outcomes. However, while the majority of patients improved, functional outcomes and quality of repair tissue were still not normal.”

This article originally appeared in Orthopedics This Week.

Recent News

  • What is minimally invasive foot and ankle surgery?
  • At Risk Foot Care: 8 Top Tips
  • Survey finds prior authorization hurdles have led to serious adverse events
  • Osteochondral Lesions of the Talus – Allograft no better than micro fracture?

Categories

  • all
  • exclusives
  • press releases
  • smpg in the news
  • technology & research
  • trending topics
  • what's new in foot and ankle surgery

Reserve Your Consultation Today!

Learn why more families in the San Francisco Bay Area chose us for their foot and ankle care!

Reserve Online
Meet Your Doctors

Learn More

Why Choose Us?

Learn More

Health Insurance Explained

Learn More

Contact Information

San Mateo Podiatry Group
1750 El Camino Real, Suite 106
Burlingame, CA 94010

Monday to Friday, 9:00 AM - 5:00 PM
Same Day Urgent Care Consults Available

Reserve Your Visit Online
Call Today: 650-342-2420

Connect

  • Home
  • News
  • Careers
  • Media Inquiries
  • Contact Us

About

  • Who We Are
  • Meet The Doctors
  • Meet The Team
  • Why Choose Us?
  • Advantage: Podiatry
  • Client Testimonials

Patient Resources

  • New Visitors
  • Your Consultation
  • Patient Portal
  • Telemedicine
  • Out of Town Patients 
  • Health Insurance FAQ
  • Financing Options

Downloads

  • Registration Forms
  • Financial Policies
  • Practice Policies
  • Privacy Notices (HIPAA)
  • Patient Education Library
  • Stretching Instructions
  • After-Surgery Instructions

© Copyright 2021 San Mateo Podiatry Group

Since 1917, A Tradition of Excellence in Foot and Ankle Care.

All Rights Reserved | Terms of Use and Privacy Policy